Calculate the Finnegan NAS to review neonatal opioid withdrawal severity, repeated-score thresholds, and category breakdowns in worksheet form.
The Finnegan Neonatal Abstinence Score (NAS) is a structured bedside scoring system for neonatal opioid withdrawal. Developed by Loretta Finnegan in 1975, it organizes withdrawal signs across three domains — CNS findings, metabolic/vasomotor/respiratory findings, and gastrointestinal findings — so repeated observations can be compared consistently over time.
The score matters because neonatal withdrawal management is based on trends, not on a single isolated number. Infants exposed to opioids in utero may begin showing symptoms over the first several days of life, and the same infant can look very different from one assessment window to the next depending on feeding, consolability, and the time since the last score.
This page keeps the Finnegan arithmetic in worksheet form. It summarizes the total, the category breakdown, and the commonly cited repeated-score thresholds that many units use as review points. It does not replace a neonatal unit protocol or physician decision-making.
Finnegan scoring is useful when it stays consistent from one observation period to the next. A worksheet helps keep the item list, the total, and the repeated-score context together without turning the calculator itself into a medication order set.
Finnegan NAS = Sum of all 24 item scores Scoring categories: • CNS (10 items): cry (0–3), sleep (0–3), Moro reflex (0–3), tremors disturbed/undisturbed (0–3 each), muscle tone (0–2), excoriation (0–1), myoclonus (0–3), seizures (0–5) • Metabolic/Vasomotor/Respiratory (9 items): sweating (0–1), fever (0–2), yawning (0–1), nasal stuffiness/sneezing/flaring (0–2), RR (0–2) • GI (5 items): sucking (0–1), feeding (0–2), vomiting (0–2), stool consistency (0–3) Maximum score: ~38 Common repeated-score review points: ≥8 (×3) or ≥12 (×2)
Result: NAS = 10 — threshold-review range.
A score of 10 with tremors (disturbed = 2), high-pitched cry (2), sleep <2 hours (2), excessive sucking (1), sneezing (1), and loose stools (2) sits in the common threshold-review range. On many units, the key next question is whether scores in that range are being sustained across repeated assessments rather than what one isolated number says.
The Finnegan NAS was developed in 1975 at Thomas Jefferson University Hospital and has been one of the most widely used withdrawal-scoring tools ever since. The modified Finnegan score, which reduced the original item count, is the version most people know today. Alternatives include the Lipsitz score, trial-specific tools such as the MOTHER NAS scale, and the newer Eat-Sleep-Console framework.
The score is most useful when it is repeated consistently over time. A single high score can matter, but most units are really trying to answer whether the infant is showing a sustained pattern of worsening withdrawal, improving with supportive care, or fluctuating around a threshold band. That is why feeding timing, consolability, and observation windows affect interpretation so much.
Low stimulation, swaddling, skin-to-skin care, breastfeeding when appropriate, rooming-in, and frequent small feeds remain central to care even when medication enters the discussion. The more reliable those supportive measures are, the more meaningful the trend in the scores becomes.
Last updated:
This worksheet sums the modified Finnegan item scores across the CNS, metabolic/vasomotor/respiratory, and GI domains, then compares the total with the repeated-score thresholds commonly cited in neonatal withdrawal pathways. It keeps the category pattern visible so serial scores can be reviewed more consistently across observation windows.
The page is not a stand-alone treatment protocol. Feeding timing, consolability, supportive care, maternal substance history, and the specific newborn-withdrawal pathway used by the unit still matter more than one isolated score.
Timing depends on the specific opioid: heroin-exposed neonates show symptoms within 24–48 hours. Methadone-exposed neonates may not show symptoms until 48–72 hours (sometimes up to 5–7 days due to methadone's long half-life). Buprenorphine-exposed neonates typically present within 24–48 hours but often with milder symptoms. Delayed onset (>5 days) can occur with long-acting opioids. Scoring should start within 2 hours of birth for at-risk infants and continue for at least 72–96 hours even if initial scores are low.
Units vary in how they handle pharmacologic treatment, but repeated high scores often prompt review of opioid-replacement options and, in some pathways, adjunctive therapy if symptoms remain difficult to control. This calculator intentionally stops at the score-review stage rather than presenting a dosing protocol.
Average hospitalization for pharmacologically treated NAS is 17–25 days (highly variable). Treatment duration depends on: the maternal substance (methadone-exposed infants have longer withdrawal than heroin or buprenorphine), polydrug exposure (benzodiazepines, SSRIs, nicotine complicate withdrawal), initial severity, and institutional protocols. Non-pharmacologically managed infants average 5–10 days. The trend toward eat-sleep-console (ESC) rather than Finnegan scoring has reduced average treatment duration and length of stay in many centers.
ESC is a newer, simplified assessment method that is increasingly replacing the Finnegan scoring system. It asks three questions: Can the baby eat ≥1 oz per feed? Can the baby sleep ≥1 hour undisturbed? Can the baby be consoled within 10 minutes? If all three answers are "yes," pharmacotherapy is not needed regardless of traditional NAS signs. Studies show ESC reduces pharmacotherapy rates by 30–50% and hospital length of stay by 5–10 days compared to Finnegan-based protocols. It emphasizes non-pharmacologic care and parent involvement.
For opioid-dependent pregnant women, medically supervised treatment is standard because abrupt cessation during pregnancy can be dangerous. After birth, breastfeeding when appropriate, rooming-in, and consistent non-pharmacologic care often reduce score severity and lower the need for medication.
Several substance classes can cause neonatal withdrawal: benzodiazepines (seizures, irritability, feeding difficulty — may have delayed onset), SSRIs/SNRIs (poor neonatal adaptation syndrome in ~30%, usually mild), alcohol (rare fetal alcohol withdrawal), barbiturates (similar to opioid withdrawal), cannabis (mild, controversial), and nicotine (irritability, poor feeding, tremors). Polydrug exposure is common and can complicate the clinical picture. The Finnegan score was designed for opioid withdrawal but some items overlap with other withdrawal syndromes.